Conclusions
Using the usual costs and patterns of treatment of invasive mycosis in Spain, voriconazole was found to be more cost effective than caspofungin for the treatment of invasive aspergillosis in patients with a bodyweight <103.42kg.
This study was funded by Pfizer S.A. Spain. The authors would like to acknowledge the assistance received from Inés Fernández and Paloma González, from Pfizer S.A. Spain.
Mercedes García and Silvia Díaz are employees of Euroclin Institute, a company that offers support to Pfizer S.A. Spain. Almudena Del Castillo and Cristina Sánchez are employees of Pfizer S.A. Spain. Neither Alfonso Domínguez-Gil nor Isabel Martín has any conflicts of interest related to the content of this study.
Reprint AddressCorrespondence and offprints: Dr Mercedes García Vargas, Health Outcomes Research Department, Medical Unit, Pfizer Spain, Avenida de Europa, 20-B, Parque Empresarial 'La Moraleja', 28108 Alcobendas, Spain. E-mail: mercedes.garcia@pfizer.com
Clin Drug Invest. 2007;27(3):197-205. © 2007 Adis Data Information BV
Cite this: Economic Evaluation of Voriconazole versus Caspofungin for the Treatment of Invasive Aspergillosis in Spain - Medscape - Mar 01, 2007.
Comments